UNIVERSITAS GADJAH MADA
Skor Systemic Inflammation Response Index (SIRI) sebagai Faktor Kesintasan 1 Tahun Pada Karsinoma Sel Hati di RSUp Dr. Sardjito Yogyakarta
Nirwan Fathur Rahman, Dr. dr. Neneng Ratnasari Sp. PD-KGEH.; dr. Fahmi Indrarti Sp. PD K-GEH
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Abul Abbas, Andrew Lichtman, S. P. (2019) *Celluler and Molecular Immunology*.

Adhoute, X. *et al.* (2016) '2016 Hepatocellular Carcinoma : Global view Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments', 8(17), pp. 703–715. doi: 10.4254/wjh.v8.i17.703.

Aino, H. *et al.* (2016) 'The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis', pp. 83–88. doi: 10.3892/mco.2016.879.

Arvanitakis, K., Mitroulis, I. and Germanidis, G. (2021) 'Tumor-Associated Neutrophils in Hepatocellular Carcinoma', pp. 1–17.

Balmasova, I. P. *et al.* (2014) 'Immunopathogenesis of chronic hepatitis B', 20(39), pp. 14156–14171. doi: 10.3748/wjg.v20.i39.14156.

Bosetti, C., Turati, F. and La Vecchia, C. (2014) 'Hepatocellular carcinoma epidemiology', *Best Practice and Research: Clinical Gastroenterology*, 28(5), pp. 753–770. doi: 10.1016/j.bpg.2014.08.007.

Caines, A. (2022) 'The Changing Global Epidemiology of Hepatocellular Carcinoma', *Clinics in Liver Disease*, 24(4), pp. 535–547. doi: 10.1016/j.cld.2020.06.001.

Chang, M. *et al.* (2000) 'Hepatitis B Vaccination and Hepatocellular Carcinoma Rates in Boys and Girls', 284(23), pp. 18–20.

Chinen, J. and Shearer, W. T. (2002) 'Molecular virology and immunology of HIV infection', *Journal of Allergy and Clinical Immunology*, 110(2), pp. 189–198. doi: 10.1067/mai.2002.126226.

Choo, S. P. *et al.* (2016) 'Comparison of hepatocellular carcinoma in Eastern versus Western populations', *Cancer*, 122(22), pp. 3430–3446. doi: 10.1002/cncr.30237.

Skor Systemic Inflammation Response Index (SIRI) sebagai Faktor Kesintasan 1 Tahun Pada Karsinoma
Sel Hati di RSUp Dr. Sardjito Yogyakarta
Nirwan Fathur Rahman, Dr. dr. Neneng Ratnasari Sp. PD-KGEH.; dr. Fahmi Indrarti Sp. PD K-GEH
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Dahlan, M. S. (2013) *Besar Sampel dan Cara Pengambilan Sampel*. Tiga. Jakarta: Salemba Medika.

Darmadi, D., Ruslie, R. H. and Pakpahan, C. (2021) 'Vascular Endothelial Growth Factor Levels Difference among Hepatocellular Cancer Patients Based on Barcelona Clinic Liver Cancer Staging', 9, pp. 797–800.

Dhanasekaran, R., Bandoh, S. and Roberts, L. R. (2016) 'Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances [version 1 ; referees : 4 approved] Referee Status ':, 5(May), pp. 1–15. doi: 10.12688/f1000research.6946.1.

Goh, G. B. B., Chang, P. E. and Tan, C. K. (2015) 'Changing epidemiology of hepatocellular carcinoma in Asia', *Best Practice and Research: Clinical Gastroenterology*, 29(6), pp. 919–928. doi: 10.1016/j.bpg.2015.09.007.

Goossens, N. and Hoshida, Y. (2015) 'Hepatitis C virus-induced hepatocellular carcinoma', pp. 105–114.

Gumilas, N. S. A. *et al.* (2019) 'Hepatitis B as hepatocellular carcinoma (HCC) risk factor in the south region of Java, Indonesia', *Journal of Physics: Conference Series*, 1246(1). doi: 10.1088/1742-6596/1246/1/012013.

Hsu, C. Y. *et al.* (2010) 'Selecting an optimal staging system for hepatocellular carcinoma: Comparison of 5 currently used prognostic models', *Cancer*, 116(12), pp. 3006–3014. doi: 10.1002/cncr.25044.

Hu, B. *et al.* (2014) 'Systemic Immune-In fl ammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma', 20(16), pp. 6212–6222. doi: 10.1158/1078-0432.CCR-14-0442.

Iadecola, C. and Anrather, J. (2011) 'The immunology of stroke: From mechanisms to translation', *Nature Medicine*, 17(7), pp. 796–808. doi: 10.1038/nm.2399.

Kanwal, F. *et al.* (2019) 'Long-Term Risk of Hepatocellular Direct Acting Antiviral Agents', 0(0), pp. 1–12. doi: 10.1002/hep.30823.

UNIVERSITAS GADJAH MADA
Skor Systemic Inflammation Response Index (SIRI) sebagai Faktor Kesintasan 1 Tahun Pada Karsinoma Sel Hati di RSUp Dr. Sardjito Yogyakarta
Nirwan Fathur Rahman, Dr. dr. Neneng Ratnasari Sp. PD-KGEH.; dr. Fahmi Indrarti Sp. PD K-GEH
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Kasper. Dennis (2015), *Harrison's Principles of Internal 19 th edition*, Mc Graw Hill Education Publisher, pp. 544-533.

Kemenkes RI (2018) 'Hasil Riset Kesehatan Dasar Tahun 2018', *Kementrian Kesehatan RI*, 53(9), pp. 1689–1699.

Kinoshita, A. *et al.* (2012) 'Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma', *British Journal of Cancer*, pp. 988–993. doi: 10.1038/bjc.2012.354.

Kristina, S. A. (2021) 'The medical cost of liver cancer in a referral hospital in Indonesia during 2020', 11(12), pp. 135–138.
doi: 10.7324/JAPS.2021.1101212.

Kudo, M. *et al.* (2020) 'A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements', *Liver Cancer*, 9(3), pp. 245–260.
doi: 10.1159/000507370.

Kulik, L. and El-serag, H. B. (2022) 'Epidemiology and Management of Hepatocellular Carcinoma', *Gastroenterology*, 156(2), pp. 477-491.e1.
doi: 10.1053/j.gastro.2018.08.065.

Kulik, L. and El-Serag, H. B. (2019) 'Epidemiology and Management of Hepatocellular Carcinoma', *Gastroenterology*, 156(2), pp. 477-491.e1.
doi: 10.1053/j.gastro.2018.08.065.

Laurent-Puig, P. and Zucman-Rossi, J. (2006) 'Genetics of hepatocellular tumors', *Oncogene*, 25(27), pp. 3778–3786. doi: 10.1038/sj.onc.1209547.

Laurentius. Lesmana (2017) 'Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati', *2017*.

Leong, T. Y. M. and Leong, A. S. Y. (2005) 'Epidemiology and carcinogenesis of hepatocellular carcinoma', *Hpb*, 7(1), pp. 5–15.
doi: 10.1080/13651820410024021.

UNIVERSITAS GADJAH MADA
Skor Systemic Inflammation Response Index (SIRI) sebagai Faktor Kesintasan 1 Tahun Pada Karsinoma Sel Hati di RSUp Dr. Sardjito Yogyakarta
Nirwan Fathur Rahman, Dr. dr. Neneng Ratnasari Sp. PD-KGEH.; dr. Fahmi Indrarti Sp. PD K-GEH
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Lu, L., Hsu, C. and Cheng, A. (2016) 'Tumor Heterogeneity in Hepatocellular Carcinoma : Facing the Challenges', pp. 128–138. doi: 10.1159/000367754.

Lv, Y. *et al.* (2017) 'Causes of peripheral cytopenia in hepatitic cirrhosis and portal hypertensive splenomegaly', *Experimental Biology and Medicine*, 242(7), pp. 744–749. doi: 10.1177/1535370217693113.

Mantovani, A. and Targher, G. (2017) 'Type 2 diabetes mellitus and risk of hepatocellular carcinoma : spotlight on nonalcoholic fatty liver disease', 5(13), pp. 1–12. doi: 10.21037/atm.2017.04.41.

Margetts, J. *et al.* (2017) 'Neutrophils : driving progression and poor prognosis in hepatocellular carcinoma ?', *Nature Publishing Group*, 118(2), pp. 248–257. doi: 10.1038/bjc.2017.386.

Mcglynn, K. A., Petrick, J. L. and London, W. T. (2022) 'Global Epidemiology of H e p a t o c e l l u l a r C a rc i n o m a An Emphasis on Demographic and Regional Variability', *Clinics in Liver Disease*, 19(2), pp. 223–238. doi: 10.1016/j.cld.2015.01.001.

Mouchli, M. *et al.* (2020) 'Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article', *Annals of Hepatology*. doi: 10.1016/j.aohep.2020.08.067.

Nault, J. (2014) 'Best Practice & Research Clinical Gastroenterology Pathogenesis of hepatocellular carcinoma according to aetiology', *Best Practice & Research Clinical Gastroenterology*, 28(5), pp. 937–947. doi: 10.1016/j.bpg.2014.08.006.

Olivia, C. *et al.* (2020) 'Risk factors of mortality in the patients with hepatocellular carcinoma : A multicenter study in Indonesia', *Current Problems in Cancer*, 44(1), p. 100480. doi: 10.1016/j.currproblcancer.2019.05.003.

Omata, M. *et al.* (2010) 'Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma', *Hepatology International*, 4(2), pp. 439–474. doi: 10.1007/s12072-010-9165-7.

UNIVERSITAS GADJAH MADA
Skor Systemic Inflammation Response Index (SIRI) sebagai Faktor Kesintasan 1 Tahun Pada Karsinoma Sel Hati di RSUp Dr. Sardjito Yogyakarta
Nirwan Fathur Rahman, Dr. dr. Neneng Ratnasari Sp. PD-KGEH.; dr. Fahmi Indrarti Sp. PD K-GEH
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Palliyaguru, D. L. and Wu, F. (2013) 'Food Additives & Contaminants : Part A Global geographical overlap of aflatoxin and hepatitis C : controlling risk factors for liver cancer worldwide', 0049.
doi: 10.1080/19440049.2012.751630.

PERKENI (2019) 'Pengelolaan dan Pengobatan Diabetes Melitus Tipe 2 Dewasa', *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*, 1, p. 132.

Petrick, J. L. *et al.* (2018) 'Tobacco , alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma : The Liver Cancer Pooling Project', *British Journal of Cancer*, (January). doi: 10.1038/s41416-018-0007-z.

van der Poll, T., Shankar-Hari, M. and Wiersinga, W. J. (2021) 'The immunology of sepsis', *Immunity*, 54(11), pp. 2450–2464.
doi: 10.1016/j.immuni.2021.10.012.

Ponnappan, S. and Ponnappan, U. (2011) 'Aging and immune function: Molecular mechanisms to interventions', *Antioxidants and Redox Signaling*, 14(8), pp. 1551–1585. doi: 10.1089/ars.2010.3228.

Qi, X. *et al.* (no date) 'Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma : A systematic review and meta-analysis of observational studies', 7(29).

Rahayu, W. P. *et al.* (2020) 'Risk estimation of hepatocellular carcinoma due to exposure to aflatoxins in maize from yogyakarta, Indonesia', *Journal of Food Quality and Hazards Control*, 7(1), pp. 45–50.
doi: 10.18502/JFQHC.7.1.2451.

Reig, M. *et al.* (2022) 'BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update', *Journal of Hepatology*, 76(3), pp. 681–693. doi: 10.1016/j.jhep.2021.11.018.

Sachdeva, M., Chawla, Y. K. and Arora, S. K. (2015) 'Immunology of hepatocellular carcinoma', 7(17), pp. 2080–2090. doi: 10.4254/wjh.v7.i17.2080.

Skor Systemic Inflammation Response Index (SIRI) sebagai Faktor Kesintasan 1 Tahun Pada Karsinoma
Sel Hati di RSUp Dr. Sardjito Yogyakarta
Nirwan Fathur Rahman, Dr. dr. Neneng Ratnasari Sp. PD-KGEH.; dr. Fahmi Indrarti Sp. PD K-GEH
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Sansone, V. *et al.* (2021) 'Comparison of prognostic scores in patients with hepatocellular carcinoma treated with sorafenib', *Clinical and Translational Gastroenterology*, 12(1), pp. 1–7. doi: 10.14309/ctg.0000000000000286.

Singal, A. G. and El-serag, H. B. (2022) 'Hepatocellular Carcinoma From Epidemiology to Prevention : Translating Knowledge into Practice', *Clinical Gastroenterology and Hepatology*, 13(12), pp. 2140–2151. doi: 10.1016/j.cgh.2015.08.014.

Singal, A. G., Lampertico, P. and Nahon, P. (2020) 'Epidemiology and surveillance for hepatocellular carcinoma : New trends', *Journal of Hepatology*, 72(2), pp. 250–261. doi: 10.1016/j.jhep.2019.08.025.

Sipeki, N. *et al.* (2014) 'Immune dysfunction in cirrhosis', *World Journal of Gastroenterology*, 20(10), pp. 2564–2577. doi: 10.3748/wjg.v20.i10.2564.

Sirivatanauksorn, Y. and Tovikkai, C. (2011) 'Comparison of Staging Systems of Hepatocellular Carcinoma', 2011. doi: 10.1155/2011/818217.

Soyuoz, A. *et al.* (2018) 'Therapeutic plasma exchange for refractory SLE: A comparison of outcomes between different sub-phenotypes', *European Journal of Rheumatology*, 5(1), pp. 32–36.
doi: 10.5152/eurjrheum.2017.17088.

Stefaniuk, P., Szymczyk, A. and Podhorecka, M. (2020) 'The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review', pp. 2961–2977.

Stockman, J. A. (2013) 'Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1', *Yearbook of Pediatrics*, 2013, pp. 312–313.
doi: 10.1016/j.yped.2012.03.092.

Su, F., Ioannou, G. N. and Ch, B. M. B. (2019) 'Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy', 13(1). doi: 10.1002/cld.781.

UNIVERSITAS GADJAH MADA
Skor Systemic Inflammation Response Index (SIRI) sebagai Faktor Kesintasan 1 Tahun Pada Karsinoma Sel Hati di RSUp Dr. Sardjito Yogyakarta
Nirwan Fathur Rahman, Dr. dr. Neneng Ratnasari Sp. PD-KGEH.; dr. Fahmi Indrarti Sp. PD K-GEH
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Tan Yifei, Wei Shiyou, Zhang Wei, Yang Jian, Yang Jiayin, Yan Lunan (2019) 'Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection : a meta-analysis and systematic review', pp. 705–713.

Toyoda, H. *et al.* (2005) 'Comparison of the Usefulness of Three Staging Systems for Hepatocellular Carcinoma (CLIP , BCLC , and JIS) in Japan', (12), pp. 1764–1772. doi: 10.1111/j.1572-0241.2005.41943.x.

Utama, A. *et al.* (2010) 'Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia', (70), pp. 1152–1160. doi: 10.1111/j.1478-3231.2010.02280.x.

Vandenbulcke, H. *et al.* (2016) 'Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis : a prospective study', *Journal of Hepatology*. doi: 10.1016/j.jhep.2016.04.031.

Varbobitis, I. and Papatheodoridis, G. V (2016) 'The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy', pp. 319–326.

Vogel, A. *et al.* (2018a) 'Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up', *Annals of Oncology*, 29(Supplement 4), pp. iv238–iv255. doi: 10.1093/annonc/mdy308.

Vogel, A. *et al.* (2018b) 'Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up', *Annals of Oncology*, 29(Supplement 4), pp. iv238–iv255. doi: 10.1093/annonc/mdy308.

Wade, A. J. *et al.* (2018) 'Community-based provision of direct-acting antiviral therapy for hepatitis C: Study protocol and challenges of a randomized controlled trial', *Trials*, 19(1), pp. 1–9. doi: 10.1186/s13063-018-2768-3.

Wang, B., Huang, Y. and Lin, T. (2020) 'Prognostic impact of elevated pre-treatment systemic immune-in fl ammation index (SII) in hepatocellular carcinoma', pp. 1–7.

UNIVERSITAS GADJAH MADA
Skor Systemic Inflammation Response Index (SIRI) sebagai Faktor Kesintasan 1 Tahun Pada Karsinoma Sel Hati di RSUp Dr. Sardjito Yogyakarta
Nirwan Fathur Rahman, Dr. dr. Neneng Ratnasari Sp. PD-KGEH.; dr. Fahmi Indrarti Sp. PD K-GEH
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Wang, H. *et al.* (2020) 'Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications', *Journal of Immunology Research*, 2020. doi: 10.1155/2020/4904217.

Wang, H. *et al.* (2021) 'The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib', (September).

Wang, T. (2021) 'Systemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE', pp. 2589–2600.

Xiao, W. *et al.* (2014) 'Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma : a meta-analysis', *BMC Cancer*, 14(1), pp. 1–10. doi: 10.1186/1471-2407-14-117.

Xu, L. *et al.* (2017) 'Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients', 8(21), pp. 34954–34960.

Zhang, Q. *et al.* (2020) 'Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies', 26(26), pp. 3720–3736. doi: 10.3748/wjg.v26.i26.3720.

Zhao, H. *et al.* (2011) 'ARID2: A new tumor suppressor gene in hepatocellular carcinoma', *Oncotarget*, 2(11), pp. 886–891. doi: 10.18632/oncotarget.355.

Zhu, R. X. *et al.* (2016) 'Epidemiology of hepatocellular carcinoma in the Asia-Pacific region', *Gut and Liver*, 10(3), pp. 332–339. doi: 10.5009/gnl15257.

Zucman-rossi, J. *et al.* (2015) 'Genetic Landscape and Biomarkers of Hepatocellular Carcinoma', *YGAST*, 149(5), pp. 1226-1239.e4. doi: 10.1053/j.gastro.2015.05.061.